The treatment landscape of both locally advanced and metastatic urothelial bladder cancer (UBC) has largely improved in the last few years due to the approval of new drugs with different mechanisms of action including immune‐checkpoint inhibitors (ICIs), and anti‐fibroblast growth factor receptor (FGFR)‐, TROP2‐ or Nectin‐4‐targeting agents. This evidence concerns the gene NECTIN4 and bladder transitional cell carcinoma.